RxDoctor Payments Data

Rajan Gulati, MD

Internal Medicine · Cuba, NYNPI 1487735155

Payments from drug & device makers

$1,399in general payments, 2019–2025

Across 43 payments — averaging $32.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$429
  • AstraZeneca$337
  • Amgen$111
  • Merck$107
  • Novartis$80
  • AbbVie$59
  • plus $275 from 8 others

What the payments were for

  • Food & beverage$1,38499%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,399 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$70,975
Medicare patients
193
Services billed
854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban335$160,020
TrulicityDulaglutide106$139,138
RexultiBrexpiprazole127$94,105
XareltoRivaroxaban199$77,608
JardianceEmpagliflozin60$51,971
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$51,722
NuplazidPimavanserin Tartrate16$50,774
EntrestoSacubitril/Valsartan12$16,826
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$11,167
FarxigaDapagliflozin Propanediol28$10,686
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,978
Atorvastatin Calcium611$8,437
Breo ElliptaFluticasone/Vilanterol11$7,127
SymbicortBudesonide/Formoterol Fumarate17$6,850
Gabapentin315$6,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$14$139,138106 claims
Otsuka America Pharmaceutical, Inc.Rexulti$34$94,105127 claims
Johnson & JohnsonXarelto$34$77,608199 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy$429$71,210110 claims
Boehringer IngelheimJardiance$57$51,97160 claims
AstraZenecaFarxiga, Symbicort$337$17,53645 claims
NovartisEntresto$80$16,82612 claims
Novo NordiskLevemir, Tresiba$37$10,68645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Cuba

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →